(146) Rezum Water Vapor Therapy for Patients with Mild, Moderate, or Severe Lower Urinary Tract Symptoms: A Retrospective Study in a Multiethnic Population

Abstract Introduction Benign prostatic hyperplasia (BPH) is a common chronic condition that associated with the development of lower urinary tract symptoms (LUTS). Symptom severity LUTS secondary to BPH can range from mild, moderate, severe and be assessed utilizing International Prostate Score (IPSS). The Rezum System (Rezum; Boston Scientific, Marlborough, MA, USA) minimally invasive surgical therapy utilizes convective radiofrequency water vapor thermal energy ablate obstructive lobes prostate, resulting in cell necrosis improvement LUTS. Objective To evaluate safety efficacy patients or BPH. Methods A single office, retrospective study was conducted on multiethnic population treated between 2017 2019. Patients were categorized into three cohorts based baseline IPSS severity: mild (IPSS ≤ 7), moderate 8-19), ≥ 20) cohorts. Outcome measures, including IPSS, quality life (QoL), maximum flow rate (Qmax), postvoid residual (PVR), alpha blockers 5-alpha reductase inhibitors usage, adverse events (AEs) collected analyzed at baseline, 1-, 3-, 6-, and/or 12-months postoperatively. Results total 238 included: 33 LUTS, 109 96 At 1-month follow-up, saw significant improvements (moderate LUTS: -3.0 [-6.0, 1.5], p<0.001; -10.0 [-16.0, -5.0], p<0.001) QoL -1.0 [-3.0, 0.0], remained durable up (p<0.001). cohort worsening by 2.0 (0.0, 12.0) (p=0.002) but returned 3-months (p=0.114). However, experienced -0.5 (-3.0, 0.0) (p=0.035) nocturia 0.0 (-1.0, 6-months (p=0.002), both which (p<0.05). Most AEs transient non-serious, gross hematuria (66.5%) being most common. There no differences point reduction, Qmax improvement, PVR AE occurrence (p>0.05). 12-months, 80.0%, 87.5%, 66.0% discontinued their medications, respectively. Conclusions provides rapid relief offered who have bothersome wish discontinue medications. Disclosure No